---
title: "Varegacestat (AL102) in Desmoid tumors: Prevalence"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Prevalence. Topics: Literature review: no published prevalence study; Company estimate: U.S. actively managed patients from physician market research, SpringWorks Therapeutics; Company estimate: U.S. patients receiving physician care from ICD-10 claims, October 2023 to October 2024, SpringWorks Therapeutics; Company statement: prevalent pool attributed to limited effect on mortality, SpringWorks Therapeutics; 1 further topic. 5 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/prevalence"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Desmoid tumors

<a id="topic-2.2.1.2.2-1"></a>

### Literature review: no published prevalence study

> “No study evaluating the prevalence of DT was identified.”
> “Few epidemiological studies providing incidence estimates of DT were identified in the literature; all these studies were conducted in European countries, and no study provided prevalence estimates.”
> “In addition, no incidence or prevalence data on children are available.”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.2.2-2"></a>

### Company estimate: U.S. actively managed patients from physician market research, SpringWorks Therapeutics

> “Based on market research studies with feedback from over 400 physicians who manage patients with desmoid tumors, we believe that approximately 50% of patients receiving a locoregional intervention, such as surgery, or off-label systemic therapies will not have a satisfactory treatment outcome and will require subsequent treatment for their desmoid tumors.”
> “Additionally, we believe that up to 90% or more of patients will eventually receive an active intervention.”
> “Based on this market research, we estimate that, in any given year over the next decade, approximately 5,500 to 7,000 desmoid tumor patients will be actively managed in the United States.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-2.2.1.2.2-3"></a>

### Company estimate: U.S. patients receiving physician care from ICD-10 claims, October 2023 to October 2024, SpringWorks Therapeutics

> “More recent analyses, including a review of International Classification of Diseases, Tenth Edition, or ICD-10, claims data between the introduction of desmoid tumor-specific ICD-10 codes in October 2023 and October 2024, reveals that there are approximately 11,000 desmoid tumor patients receiving physician care annually in the United States.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-2.2.1.2.2-4"></a>

### Company statement: prevalent pool attributed to limited effect on mortality, SpringWorks Therapeutics

> “Desmoid tumors, despite being highly morbid, typically have a limited impact on mortality. Due to this limited impact on overall lifespan and historical lack of effective treatment options, we believe that there is a sizable prevalent pool of desmoid tumor patients who could potentially benefit from an effective, FDA-approved treatment.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-2.2.1.2.2-5"></a>

### Company estimate: U.S. actively managed patients, Immunome

> “Desmoid tumors often strike in young adulthood, with 1,000-1,650 patients diagnosed each year and 10-11,000 actively managed patients in the US”
> “Bektas et al., Advances in Therapy, 2023”
> “10-11k Actively Managed Patients (US)”
> “1) Immunome Analysis”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
